Supernus Pharmaceuticals (LTS:0LB2) Dividends per Share: $0.00 (TTM As of Mar. 2026)


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $47.91
GF Value $38.90
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Dividends per Share?

Supernus Pharmaceuticals LTS:0LB2 -0.75% 88 Dividends per Share is $0.00 as of Mar. 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $38.90 (Modestly Overvalued).

Supernus Pharmaceuticals's dividends per share for the three months ended in Mar. 2026 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, Supernus Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Supernus Pharmaceuticals  (LTS:0LB2) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Supernus Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.015
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Dividends per Share Related Terms

Supernus Pharmaceuticals Dividends per Share Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Dividends per Share Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0LB2 vs BCRX, PBH, RGC: Dividends per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Supernus Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Dividend Yield % falls into.


LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of $0.00 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Dividends per Share of $0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Dividends per Share too high?
Supernus Pharmaceuticals' current Dividends per Share is $0.00. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Dividends per Share compare to BCRX and PBH?
Supernus Pharmaceuticals' Dividends per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Dividends per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $38.90, compared to a current price of $47.91 — trading 23.2% above its estimated fair value. The current Dividends per Share is $0.00. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Dividends per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $47.91 is trading 23.2% above its estimated GF Value™ of $38.90. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Dividends per Share: $0.00
  • GF Value™: $38.90 vs. price of $47.91 (23.2% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.91
Price
$38.90
GF Value